There is a significant risk of development of pigmentary changes during treatment with targeted anti-cancer therapies, according to a recent study. Therefore, appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life. A comprehensive search was conducted to identify studies reporting targeted therapy–induced pigmentary changes. The incidence and relative risk were calculated and case reports and series were reviewed to understand clinical characteristics. A total of 8,052 patients from 36 clinical trials were included. Researchers found:
- The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% and 21.5%, respectively.
- The relative risk of all-grade pigmentary changes of skin and hair were 93.7 and 20.1.
- Across 53 case reports/series (n=75 patients), epidermal growth factor receptor and breakpoint cluster region-abelson inhibitors were the most common offending agents.
Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. [Published online ahead of print September 14, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.06.044.
This Week's Must Reads
Opioids and the Dermatology Medicare Population, JAMA Dermatology; ePub 2018 Feb 7; Cao, et al
Significant Care Costs Associated with Cellulitis, J Am Acad Dermatol; ePub 2018 Feb 7; St. John, et al
An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al
Underlying Disease Impact on Pyoderma Gangrenosum, J Am Acad Dermatol; ePub 2018 Feb 10; Kaffenberger, et al
FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8
Must Reads in Pigmentation Disorders
Anti-Cancer Therapies, Pigmentary Changes Linked, J Am Acad Dermatol; ePub 2017 Sep 14; Dai, Belum, et al
Morphologic CALM Features Help Determine Treatment, JAMA Dermatol; ePub 2017 Aug 30; Belkin, et al
MKTP Procedure Satisfactory for Leukoderma Treatment, J Am Acad Dermatol; ePub 2017 May 11; Silpa-Archa, et al
Hyperpigmentation Patients: Less Sunscreen Usage, J Am Acad Dermatol; ePub 2017 Feb 15; Maymone, et al
Risk Factors for Vitiligo Examined in Women, J Invest Dermatol; ePub 2017 Feb 14; Dunlap, et al